MAIA Biotechnology’s Part 2 Research Of THIO In Non-Small Cell Lung Most cancers Reveals Optimistic Interim Survival Advantages – Regeneron Prescribed drugs (NASDAQ:REGN), MAIA Biotechnology (AMEX:MAIA)

MAIA Biotechnology Inc. MAIA, a clinical-stage biopharmaceutical company centered on growing and commercializing focused immunotherapies for most cancers, reported constructive interim survival advantages in a part 2 research of THIO, its lead remedy to battle superior non-small cell lung most cancers (NSCLC). NSCLC is a illness during which most cancers cells kind within the tissues of the lung. It is the most typical type of lung most cancers within the U.S., accounting for 81% of lung cancer diagnoses. The five-year survival charge for the sort of most cancers is 28%. 

Within the part 2 medical trial dubbed THIO-101, MAIA is evaluating THIO sequenced with Regeneron Prescribed drugs Inc.’s REGN immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in sufferers with superior NSCLC who failed two or extra standard-of-care remedy regimens. As of August, 16 sufferers had survival follow-ups surpassing 12 months, together with 9 sufferers of their third line of therapy. Interim median survival follow-up in third-line sufferers was 10.6 months. Three of the trials’ earliest sufferers enrolled are nearing 17-month survival advantages. 

“THIO is displaying a survival profit for sufferers with superior NSCLC. We’re on monitor to realize our survival objectives in third-line remedy,” stated Vlad Vitoc, M.D., Chairman and Chief Govt Officer of MAIA. “THIO’s outperformance to this point helps our thesis that our telomere concentrating on agent may turn out to be a therapy choice for folks affected by superior NSCLC.”

Attacking Most cancers Spreading Telomeres 

THIO targets and attacks telomeres which play a key position in serving to most cancers cells dwell and unfold. Telomerase is comprised of DNA sequences and proteins and sits on the finish of chromosomes, capping and defending them. Telomerase expression most frequently happens within the early levels of development and improvement in people and in just a few cells of adults. However in almost all cancers, telomerase is current, permitting most cancers cells to divide and unfold. Greater than 80% of NSCLC tumors have telomerase expression. THIO induces telomerase-dependent telomeric DNA modification, DNA injury responses and selective most cancers cell demise.  

All The Information Coming Collectively 

The 12-month survival information corresponds to MAIA’s most up-to-date information from THIO-101 demonstrating favorable illness management and general response charges. In June, the corporate introduced new efficacy information that confirmed a good overall response rate (ORR) of 38%, a illness management charge (DCR) of 85% and a median progression-free survival (PFS) of 5.5 months from THIO + CPI in third-line therapy. The info was introduced in a poster session on the American Society of Scientific Oncology (ASCO) 2024 Annual Assembly on June 3, 2024. The first targets of the THIO-101 part 2 trial are to look at the protection and tolerability of THIO as an anticancer drug and as an immune system primer and to look at the medical efficacy of THIO within the type of ORR.

“All distinctive measures of efficacy in our trial to this point have exceeded our personal expectations and outperformed customary of care therapies,” stated Vitoc when the data was released. “The info introduced at ASCO advances THIO’s wonderful medical profile as a powerful, secure, and extremely efficient different for sufferers who progressed following chemotherapy and different out there therapies. We eagerly anticipate full efficacy information from THIO-101 within the second half of this yr.”

THIO appears to be displaying promise in combating one of the vital frequent types of lung most cancers, however that is not all. If this therapy proves efficient, as the corporate believes, MAIA plans to make use of THIO in treating different types of most cancers, reminiscent of hepatocellular carcinoma (HCC), small cell lung most cancers (SCLC) and malignant gliomas – indications to which THIO has been granted Orphan Drug Designation by the U.S. FDA. With the dimensions of the most cancers therapy market poised to hit $521 billion by 2033, rising at a CAGR of 8.9% over 2023-2033, MAIA could also be one firm to concentrate to. 

Featured photograph by motorolka on  Shutterstock.

This publish comprises sponsored content material. This content material is for informational functions solely and never supposed to be investing recommendation.